Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

KRT5 Antibodies

Cytokeratin 5/6 (CK5) is a type II cytokeratin protein encoded by the KRT5 gene on chromosome 12q13.13. It consists of 631 amino acids and has a molecular weight of approximately 62 kD. CK5 undergoes post-translational modifications such as phosphorylation, glycosylation, and the formation of disulfide bonds, which contribute to its structural integrity and function. As a member of the cytoskeletal intermediate filament family, CK5 is primarily an intracellular protein that maintains the structural integrity of epithelial cells, particularly in the skin, respiratory tract, and mammary glands. It provides mechanical support and resistance to mechanical stress, contributing to the stability and elasticity of epithelial tissues. The expression of KRT5 is regulated by various factors, including developmental cues, tissue-specific transcription factors, and signaling pathways involved in epithelial differentiation. Mutations in the KRT5 gene are associated with various skin disorders, such as epidermolysis bullosa simplex, characterized by blistering and fragility of the skin and mucous membranes.

This protein is considered a basal membrane marker of myoepithelial and mesothelial cells. In cancer, KRT5 expression is often associated with basal-like breast carcinomas, squamous cell carcinomas, and some types of lung adenocarcinomas. Its presence or absence in tumor cells can provide valuable diagnostic and prognostic information, aiding in subtype classification and predicting clinical outcomes. Additionally, alterations in KRT5 expression have been associated with various pathological conditions, including epithelial cancers such as squamous and basal cell carcinoma. KRT5 expression patterns have been utilized as diagnostic markers for distinguishing different subtypes of epithelial tumors and aiding in their classification.

Additionally, KRT5 expression has been implicated in the prognosis of certain cancers, with higher levels often correlating with more aggressive disease behavior and poorer patient outcomes. However, the prognostic value of KRT5 expression may vary depending on the specific cancer type and clinical context. Further research into the regulation and functional implications of KRT5 expression in disease settings may provide valuable insights for developing novel therapeutic strategies and personalized treatment approaches.

NeoBiotechnologies offers a variety of antibodies against KRT5 that have been validated for flow cytometry, immunofluorescence, immunohistochemistry, and Western blotting, as well as a HuProt-validated option. Additionally, we hold exclusive rights to KRT5 antibodies available for licensing or collaboration [https://www.neobiotechnologies.com/shop/?s=KRT5].


Keratin, type II cytoskeletal 5, 58 kDa cytokeratin, Cytokeratin-5, Keratin-5, Type-II keratin Kb5, CK5; Keratin-5; KRT5; Cytoskeletal 6A; KRT6A

Research Areas

Apoptosis, Autophagy, Breast Cancer, Cancer, Cardiovascular, Cell Biology, Cellular Markers and Tags, Developmental Biology, Endocrine, Epigenetics, Gastrointestinal Tract, Hypoxia, Immuno Oncology, Immunology, Kidney, Lymphatic, Metabolism, Microbiology, Muscle, Neuroscience, Pancreatic Cancer, Prostate Cancer, Skin, Stem Cell, AKT Signaling, Angiogenesis, Articular Cartilage Extracellular Matrix, B Cell Markers, Basal Cell Marker, BBB VCAM-1 Signaling, Bladder Cancer, Cardiac Stem Cells, Colon Cancer, Complement System, CTLA-4 blockade immunotherapy, Cytokine Signaling, Defective Intrinsic Apoptosis, Dendritic Cell Marker, Endothelial Cell Marker, Hematopoietic Stem Cells, Immune checkpoint, Infectious Disease, Lung Cancer, MAPK Signaling, Mast Cell Marker, Mesenchymal Stem Cell Differentiation, Mitochondria Marker, Neural Stem Cells, Neuroinflammation, Nuclear Marker, Ovarian Cancer, PD-1 blockade immunotherapy, Signal Transduction, Stem Cell Differentiation, Transcription Factors

Showing all 16 results


Showing all 16 results


We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.